Skip to main content
Veterinary Medicines

Therios 300 mg palatable tablets for dogs

Authorised
  • Cefalexin monohydrate

Product identification

Medicine name:
Therios 300 mg palatable tablets for dogs
THERIOS
Active substance:
  • Cefalexin monohydrate
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Cefalexin monohydrate
    315.54
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01DB01
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:
  • Polyvinylchloride blister heat sealed with an aluminium cover foil. Pack sizes: Cardboard box with 20 blisters of 10 tablets
  • Polyvinylchloride blister heat sealed with an aluminium cover foil. Pack sizes: Cardboard box with 1 blister of 10 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Ceva Salute Animale S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Ceva Sante Animale
Responsible authority:
  • Ministry Of Health
Authorisation number:
  • 104316
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0516/001
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Luxembourg
  • Netherlands
  • Norway
  • Portugal
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 10/04/2024
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."